| Autor: |
Manuel Graf, Sae Lim von Stuckrad, Akinori Uruha, Jens Klotsche, Lydia Zorn-Pauly, Nadine Unterwalder, Thomas Buttgereit, Martin Krusche, Christian Meisel, Gerd R Burmester, Falk Hiepe, Robert Biesen, Tilmann Kallinich, Werner Stenzel, Udo Schneider, Thomas Rose |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
RMD open. 8(1) |
| ISSN: |
2056-5933 |
| Popis: |
ObjectiveTo evaluate sialic acid binding Ig-like lectin 1 (SIGLEC1) expression on monocytes by flow cytometry as a type I interferon biomarker in idiopathic inflammatory myopathies (IIM).MethodsWe performed a retrospective analysis of adult and paediatric patients with the diagnosis of IIM. SIGLEC1 expression was assessed by flow cytometry and was compared with Physician Global Assessment or Childhood Myositis Assessment Scale disease activity scores. Mann Whitney U test and receiver operating characteristic curves were used for cross-sectional data analysis (n=96), two-level mixed-effects linear regression model for longitudinal analyses (n=26, 110 visits). Response to treatment was analysed in 14 patients within 12 months, using Wilcoxon test. SIGLEC1 was compared with interferon-stimulated gene 15/MxA status by immunohistochemical staining of muscle biopsies (n=17).Results96 patients with adult (a) and juvenile (j) dermatomyositis (DM, n=38), antisynthetase syndrome (AS, n=19), immune-mediated necrotising myopathy (IMNM, n=8), inclusion body myositis (IBM, n=9) and overlap myositis (n=22) were included. SIGLEC1 distinguished significantly between active and inactive disease with an area under the curve of 0.92 (95% CI 0.83 to 1) in DM and correlated with disease activity longitudinally (aDM: standardised beta=0.54, pConclusionSIGLEC1 is a candidate biomarker to assess type I interferon activity in IIM and proved useful for monitoring disease activity and response to treatment in juvenile and adult DM. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
